

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
4 March 2004 (04.03.2004)

PCT

(10) International Publication Number
WO 2004/018492 A1

(51) International Patent Classification⁷: **C07H 19/056**

(21) International Application Number:
PCT/EP2003/008627

(22) International Filing Date: 5 August 2003 (05.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/402,788 12 August 2002 (12.08.2002) US

(71) Applicant: **F. HOFFMANN-LA-ROCHE AG** [CH/CH];
124 Grenzacherstrasse, CH-4070 Basle (CH).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors: **DONG, Zhiming**; 2803 Hermitage Lane, Florence, SC 29501 (US). **ZHANG, Pingsheng**; 3312 Aberdeen Court, Florence, SC 29501 (US).


(74) Agent: **RAUBER, Beat**; 124 Grenzacherstrasse, CH-4070 Basle (CH).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.


(54) Title: PROCESS FOR PRODUCING A RIBOFURANOSE



(57) Abstract: A new process for producing a levovirin intermediate of the formula is described. Levovirin is a nucleoside antiviral.


Case 21337Process for Producing a Ribofuranose

The compound, levovirin, is a known antiviral agent having the formula:



I


Levovirin has been produced from a 1, 2, 3, 5-tetra-O-acetyl-L-ribofuranose of the
5 formula:



II


In accordance with prior procedures, the β -anomer of the compound of Formula II, *i.e.*,
the compound of Formula II-A, is converted to levovirin by the following reaction
10 scheme:

- 2 -



In this reaction scheme, the pure β -1, 2, 3, 5-tetra-O-acetyl-L-ribofuranose (II-A) is used as the starting material. Although pure β -1, 2, 3, 5-tetra-O-acetyl-L-ribofuranose is commercially available, its price is high. Therefore, the cost of levovirin produced by this method has been expensive. In view of the fact that the compound of Formula II-A is difficult to produce inexpensively, this also has been a major problem with this synthesis.

As disclosed in Ramasamy, Tam, et al., *J. Med. Chem.*, 43:1019 (2000), the compound of Formula II-A has been produced from L-ribose which has the formula:




V

This synthesis has involved eight evaporation to dryness steps and sixteen extraction operations to produce the compound of Formula II-A in pure form for its conversion to the compound Levovirin. This process has not been suitable for scale up.

- 3 -

In 1968, Guthrie and Smith in *Chem., Ind.*, 547-548 (1968) proposed a method for converting D-ribose into β -1, 2, 3, 5-tetra-O-acetyl-D-ribofuranose, an enantiomer of the compound of Formula II-A. This method contained three chemical transformations, the acetal formation, acetylation, and acetolysis. Ramasamy, et al's synthesis followed
5 Guthrie's synthetic strategy in which the acetal formation was effected in methanol and HCl, the acetylation was carried out with acetic anhydride in pyridine, and the acetolysis was conducted in acetic acid and acetic anhydride in the presence of concentrated sulfuric acid. The crude product was a mixture of α/β -anomers of 1, 2, 3, 5-tetra-O-acetyl-L-ribofuranose and the pure β -anomer of 1, 2, 3, 5-tetra-O-acetyl-L-ribofuranose
10 was obtained in 57% overall yield via recrystallization from ethyl ether.

This cumbersome procedure producing poor yields was considered necessary since it was believed that only the β -anomer of Formula II-A could be used in the synthesis of levovirin of Formula I. Therefore, in this procedure, the compound of Formula II-A had
15 to be purified and separated from its α -anomer, the compound of Formula II-B



II-B

Therefore, under the prior procedures, it was believed that it was necessary to separate and remove the α -1, 2, 3, 5-tetra-O-acetyl-L-ribofuranose of Formula II-B from the
20 compound of Formula II in order to carry out this synthesis. This has involved costly separation techniques and led to reduced yields. In summary, these processes have made the production of levovirin of Formula I costly.

Object of the present invention therefore is to provide an improved process to intermediate of formula IV which itself can easily be converted into levovirin.

25 In accordance with this invention, it has surprisingly been found that α -1, 2, 3, 5-tetra-O-acetyl-L-ribofuranose of Formula II-B can contrary to the teachings in the state of the art be converted to the compound of Formula IV which is an intermediate for levovirin.

In this manner, any mixture of the compound of Formula II-A and II-B can be converted to levovirin easily without separation. With this discovery, levovirin can be easily and
30 cheaply produced from L-ribose (V). Because of the fact that the compound of Formula II-B can be converted to the compound of Formula IV, an intermediate for levovirin, the subject invention provides an easy method for preparing the compound of Formula II in


high yields, without costly and yield lowering purification and separation techniques. These high yields are translated into the high yields of the compound of Formula I, levovirin.

In the diagrams, a bond indicated by a ($\blacktriangleleft$) indicates the substituent above the plane of the molecule. On the other hand, a bond indicated by a ($\blacktriangleright$) indicates that the substituent is below the plane of the molecule. When a ($\sim$) is used, this indicates that the bond constitutes a mixture of the α - and β -anomers; some above the plane and some below the plane of the molecule.

10 In accordance with this invention, it has been found that the stereoisomer, the compound of Formula II-B, can be converted directly to the compound of Formula IV in the same manner as the compound of Formula II-A. Therefore, a mixture of the compound of Formula II-A and II-B can be converted to the compound of Formula IV without separation or purification. This opens a new method for preparing the
15 compound of Formula II from L-ribose of Formula V.

In accordance with this invention, the L-ribose is converted to the compound of Formula II by the following reaction scheme:

- 5 -



R can be lower alkyl containing from 1 to 4 carbon atoms such as methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl and t-butyl. It is preferred that R in the above reaction scheme be methyl. The term lower alkanol designates an aliphatic lower alkanol containing from 1 to 4 carbon atoms. Lower alkanols are lower alkyl alcohols, where lower alkyl is defined as above. The preferred lowered alkanol is methanol.

In the first step of the above reaction scheme, the compound of Formula V, i.e., L-ribose is converted into the acetal of Formula VI. Any conventional method of forming an acetal can be utilized to affect this conversion. Generally, this reaction is carried out by reacting the L-ribose with a lower alkanol, preferably methanol in the presence of an acid, generally a strong inorganic acid. Any conventional, strong, inorganic acids can be utilized such as hydrochloric acid, sulfuric acid, etc. The acid catalyzes the reaction to produce the acetal of Formula VI. Generally, this reaction is carried out in the presence of excess alkanol as the solvent medium. This reaction can be carried out at room temperature and atmospheric pressure. Normally temperatures range from about 0°C to about 30°C, preferably from about 18°C to about 25°C.

The conversion of compound V to the compound of Formula VI can be stopped by neutralizing the acid in the reaction medium containing the lower alkanol, which reaction medium was used to produce the acetal of Formula VI. Neutralization is
5 achieved by adding a base to this reaction medium. Any conventional base can be utilized for neutralizing the reaction medium. However, among the preferred bases are the weak inorganic or organic bases, such as alkali metal salts, particularly sodium carbonate, lithium carbonate, and lithium acetate with lithium carbonate and lithium acetate being preferred. Any conventional method of neutralizing the reaction medium to a pH of
10 from 4 to 7, preferably from 5.0 to 6.5 can be utilized to stop this reaction. Therefore, the base should be added until a pH of from 5 to 7 is achieved. After the reaction is stopped the rest of the reactions to produce the compound of Formula II, i.e. acetylation and acetolysis, are carried out in a solvent medium containing acetic acid. It is through the use of a reaction medium containing acetic acid for both acetylation and acetolysis that
15 high yields of the compound of Formula II are obtained. The use of acetic acid as the solvent medium allows simple procedures to produce the compound of Formula II, either as a pure α -anomer, pure β -anomer or as mixture of these anomers. In this manner all the "evaporation to dryness" and extraction operations used in the previous methods are eliminated and the overall operation is greatly simplified.

20

In order to utilize acetic acid as the solvent medium in the production of the compound of Formula VII from the compound of Formula VI, the lower alkanol solvent in the reaction medium is removed and replaced by acetic acid. The solvent exchange is accomplished by replacing the lower alkanol with acetic acid. Any conventional method
25 of removing the lower alkanol from the reaction mixture which produces the compound of Formula VI can be utilized. This can be accomplished by distilling off lower alkanol from the reaction medium and thereafter adding acetic acid. In the acetic acid solvent medium, the compound of Formula VI is converted to the compound of Formula VII by the addition of acetic anhydride. In carrying out this reaction temperatures of from
30 about 60°C to 110°C are generally utilized with temperatures of from about 90°C to 105°C being especially preferred. This reaction is carried out for a period of time sufficient to produce the triacetate of Formula VII.

The triacetate compound of Formula VII in the acetic acid reaction medium can be
35 directly converted to the tetra acetate compound of Formula II by acetolysis utilizing a

strong acid such as sulfuric acid. While sulfuric acid is exemplified, any strong acid can be utilized to carry out this reaction such as the strong inorganic acids which include hydrochloric or hydrobromic acid. This acetolysis reaction occurs via the elimination of the alkoxy group (such as methoxy) and the subsequent addition of the acetoxy group to
5 produce the compound of Formula II. The acetolysis reaction is reversible and the reaction is driven to completion by the consumption of methanol with acetic anhydride. The use of acetic anhydride in an acid reaction medium accomplishes the conversion to the compound of Formula II in a single reaction medium without extensive isolation steps. In carrying out this reaction, temperature and pressure are not critical and this
10 reaction can be carried out at room temperature and atmospheric pressure. In carrying out this reaction, temperatures of from about 0°C to 30°C are generally utilized with temperatures of from about 18°C to 25°C being preferred.

The conversion of the compound of Formula VI to the compound of Formula II can be
15 carried out in a single reaction medium without changing solvents or materials by the simple addition of acetic anhydride followed by the addition of a strong mineral acid to produce the compound of Formula II. The acetolysis reaction medium in which the compound of Formula II is formed is then neutralized to stop the reaction in the same way described hereinbefore in connection with the reaction medium in which the
20 compound of Formula VI is produced.

The compound of Formula II thus produced which consists of the α - and β - anomers can be utilized in the conversion of the compound of Formula II to the compound of Formula IV by reaction with triazole methylester of Formula III. This conversion is
25 carried out at a temperature from about 90°C to about 130°C. In accordance with this invention both the α - and β - anomers are converted, by reaction with the compound of Formula III, to the compound of Formula IV having the β configuration with respect to the triazole methylester portion of this molecule.

30 If it is desired to isolate the β -anomer of Formula II-A from the mixture of Formula II produced in the acetolysis reaction, this can be done by adding water to the reaction mixture and cooling the reaction mixture to a temperature of from about 0°C to about 10°C. In this manner the compound of Formula II-A, in its pure form, is produced in accordance with this invention, by simply adding water to the reaction mixture in which
35 the compound of Formula II is formed and upon cooling to the aforementioned

temperatures, the compound of Formula II-A precipitates. In this manner a simple procedure is provided for isolating the compound of Formula II-A in pure form without the presence of the other anomer of Formula II-B. If one wishes to obtain the compound of Formula II-B, this is done after the compound of Formula II-A is separated out of the reaction medium by extracting the mixture of compounds of Formula II-A/B from the reaction medium and a subsequent isolation of the compound of Formula II-B in pure form from this mixture via column chromatography. Any conventional method of extracting the compounds of Formula II-A/B from the reaction mixture can be carried out such as by utilizing a low boiling organic solvent such as a halogenated hydrocarbon, an ester, and an ether, or their combinations. Any conventional method of isolating the compound of Formula II-B by column chromatography can be carried out such as by using silica gel and eluting with a combination of low boiling organic solvents. In this manner pure compound of Formula II-B can be obtained without the presence of its anomer of Formula II-A.

15

In accordance with this invention, the compound of Formula II need not be separated into its anomers for conversion to levovirin. The mixture of the compounds Formula II-A and II-B can be directly converted without separation of anomers to the compound of Formula IV by reaction with the compound of Formula III in the aforementioned manner to produce the desired configuration of the compound of Formula IV so that it can be converted to levovirin.

20

In accordance with this invention any mixture of anomers of the compound of Formula II can be converted directly to the compound of Formula IV. The conversion of Formula V to the compound of Formula II, in accordance with the above scheme can produce the compound of Formula II as a mixture containing at least ten mole percent (10 mole %) of the α anomer and at most ninety mole percent (90 mole %) of the β anomer depending upon the reaction conditions. Therefore, in accordance with this invention any mixture of anomers, even those containing as little as ten mole percent (10 mole %) of the α -anomer and at most ninety mole percent (90 mole %) of the β -anomer or even one hundred mole percent (100 mole %) of the α -anomer can be converted to the compound of Formula IV. As is set forth in accordance with this invention, the pure α -anomer can be converted to the compound of Formula IV.

25

30

As seen from the above, there is a great advantage of the process of this invention since a mixture of α/β -1, 2, 3, 5-tetra-O-acetyl-L-ribofuranoses can be used to prepare levovirin. In the existing processes, pure β -tetra-O-acetyl-L-ribofuranose was only used to prepare the compound of Formula IV. The conversion of L-ribose (V) to the 1, 2, 3, 5-tetra-O-acetyl-L-ribofuranose of Formula II produces a molar mixture of β/α -anomers usually ranging from 2:1 to 3:1. If only the β -anomer is utilized, at least 25% of the products are wasted. In addition, there will be some β -anomer losses during its isolation (crystallization). L-ribose (V) is a fairly expensive material.

10 In the examples, EtOAc is ethyl acetate and TBME is tertiary butyl methyl ether. All of the solvent ratios are designated as parts by volume. The ratio of α/β is given as a mole ratio. Hence a 3:1 mixture of α/β is 3 moles of the α -anomer per mole of the β -anomer in the mixture.

15 EXAMPLE 1

Preparation of a dichloromethane solution of crude β/α -1,2,3,5-tetra-O-acetyl-L-ribofuranose

A dry, clean, 1L, 4-neck round bottom flask was charged with 100 g of L-ribose and 20 500 ml of methanol. The mixture was stirred at 20°C while 9.6 g of 95% sulfuric acid was slowly added. After the addition the mixture was stirred at 20°C for 3h to complete the transformation of L-ribose to Methyl L-ribofuranoside. To this reaction mixture was slowly added 11.7 g of lithium carbonate. The mixture was stirred for 30 minutes. Methanol (320 g) was distilled out under reduced pressure (bath temperature: 45°C). To 25 the mixture was added 360 g of acetic acid. The distillation was continued until 340 g liquid was distilled out (high vacuum, bath temperature: 63 °C, pot temperature should be controlled not to exceed 52°C). The bath temperature was lowered to 50°C and 251.6g of acetic anhydride was added. After the addition the mixture was held for 1h and then heated to 100°C and held for 4h to complete the formation of methyl 2,3,5-tri-O-acetyl- 30 L-ribofuranoside. The mixture was then cooled to 20±5°C (pot temperature) and 52.6 g of 95% sulfuric acid was slowly added. The addition rate should be controlled so as to ensure that the pot temperature is 20±5°C. After the completion of the addition the mixture was stirred for 30 min at 20±5°C. Then, 95.2 g of acetic anhydride was slowly added in 2 hr while maintaining the pot temperature at 20±5°C. After the addition the

mixture was stirred at $20\pm 5^{\circ}\text{C}$ (pot temperature) for 30 minutes to finish the transformation to beta-/alpha-1, 2, 3, 5-tetra-O-acetyl-L-ribofuranoses. The mixture was neutralized with 52.1 g of lithium carbonate and then was concentrated under reduced pressure until over 419 ml of liquid was distilled out (vacuum: 60 mbar, bath temperature: 60°C , final pot temperature: 57°C). The mixture was cooled to $25\pm 5^{\circ}\text{C}$ and to it was added 150 ml of dichloromethane and 400 ml of water. The mixture was stirred at moderate speed for 30 minutes. The stirring was stopped and the mixture was held still for 15 min. The organic phase was separated. To the aqueous layer in the pot was added another 150 ml of dichloromethane. The mixture was stirred at moderate speed for 15 minutes and then held still for 15 min. The organic phase was separated. Both organic layers were combined and washed with 160 ml of 4% sulfuric acid. The pH of the aqueous phase should be below 2 at this point. The organic phase was separated as a clear light-yellow solution, which typically contained ~11% of alpha-1, 2, 3, 5-tetra-O-acetyl-L-ribofuranoses and ~27% of beta-1,2,3,5-tetra-O-acetyl-L-ribofuranoses .

15

EXAMPLE 2

Preparation of methyl 1-(2,3,5-tri-O-acetyl-beta-L-ribofuranosyl)-1,2,4-triazole-3-carboxylate using a Mixture of β/α -1,2,3,5-tetra-O-acetyl-L-ribofuranose

A 2 l flask was charged with 80.5 g of triazole methylester, the above dichloromethane solution of β/α -1,2,3,5-tetra-O-acetyl-L-ribofuranose, and 37 g of acetic anhydride at ambient temperature. The mixture was distilled at atmospheric pressure (bath temperature, 90°C). When the pot temperature reached 85°C and the distillation became very slow, vacuum was applied (up to 30 mbar) and the distillation was continued for 40 minutes at 90°C (bath temperature) and then for another 40 minutes at 120°C (bath temperature, the pot temperature reached 117°C). The vacuum was released and 843 mg of trifluoro methane sulfonic acid (triflic acid) was slowly added. After the addition the vacuum was restored and the mixture was stirred at $115\pm 5^{\circ}\text{C}$ (pot temperature) for 4h. Upon the completion of the reaction the mixture was cooled to 70°C and to it was added 750 ml of ethyl alcohol. When a homogeneous solution was formed the mixture was cooled to 50°C and held until heavy precipitation formed (seeding might be necessary). The mixture was then slowly cooled to -5°C (bath temperature) in 2h and held for at least 2 h. The solid was filtered, washed with 100 ml of cold ethyl alcohol, and dried under vacuum at 50°C for 17h to give 192.7 g (75.1% yield from L-ribose) of methyl 1-

(2,3,5-tri-O-acetyl-beta-L-ribofuranosyl)-1,2,4-triazole-3-carboxylate as an off-white solid.

EXAMPLE 3

5 Preparation of pure beta-1,2,3,5-tetra-O-acetyl-L-ribofuranose

To a 1 l dry, clean round bottom jacketed flask were added 50.0 g of L-ribose and 400 g of dry Methanol. To this mixture was added 4.60 g of 95% sulfuric acid. After the addition the mixture was stirred at ambient temperature for 3 hr. To the content was added 5.85 g
10 of lithium carbonate in one portion and the mixture was stirred at ambient temperature for 30 min. The mixture was subject to vacuum distillation at bath temperature 30°C (pot temperature 18°C) till 320 g methanol was collected. The distillation was stopped and 103g of acetic acid was added. The vacuum distillation was reassumed (at bath temperature 40°C) till 89 g distillate was collected. The distillation was again stopped and
15 146 g of acetic acid was added. Vacuum distillation was reassumed at bath temperature 40°C and then slowly increased to 50°C to distill out about 140 g of liquid. To this mixture was added 125.8 g of acetic anhydride. The mixture was heated to *ca.* 100±5°C and maintained for 5±1 hr. The mixture was then cooled to 20°C and to it was slowly added 26.3 g of 95% sulfuric acid over 30 min while controlling pot temperature not
20 exceeding 25°C. After the addition the mixture was stirred for 30 min at 20±5°C. 47.6 g of acetic anhydride was added slowly over 2 hrs at 20±5°C. After addition, the content was stirred for 1 hr at 20±5°C. To this mixture was slowly added 26.05 g of lithium carbonate. After the addition the mixture was stirred for 30 min. The mixture was subject to vacuum distillation at bath temperature 50°C (pot temperature 37°C) till about 150 g
25 of liquid was collected. To 3/5 portion of above residual content was added 60 g of water. The mixture was stirred for 30 min at bath temperature 50°C (pot temperature 47°C), then cooled to 20°C over 1 hr and held for at least 30 min. To the slurry was added slowly a mixture of 30 g of 2-propanol and 120 g of water over 1 hr. The mixture was then further cooled to *ca.* 0-5°C and aged for at least 2 hrs. The solid was filtered, washed with
30 2x36g =72 g of water, and dried under high vacuum at 40°C for 24 hrs to afford 38.27g (60.2% yield from L-ribose) of pure beta-1,2,3,5-tetra-O-acetyl-L-ribofuranoses as white solid.

EXAMPLE 4

Preparation of pure alpha-1, 2, 3, 5-tetra-O-acetyl-L-ribofuranose

The mother liquor obtained after the precipitation of pure beta-1, 2, 3, 5-tetra-O-acetyl-L-ribofuranose was extracted with 2X100 ml=200 ml of 3:7 mixed solvents of EtOAc/TBME. The combined organic layers were concentrated to almost dryness. The residue was subjected to a azeotropic distillation with 20 ml of toluene to remove residual water. The resulting mixture (13g) was colorless oil that contained a 3:1 mixture of α/β -1, 2, 3, 5-tetra-O-acetyl-L-ribofuranoses. Part of the mixture (12g) was subjected to a flash column chromatography (140 g silica gel), eluting with a mixed solvents of EtOAc/petroleum ether (9:31), to give 4.8 g of alpha-1,2,3,5-tetra-O-acetyl-L-ribofuranose (97.1% area purity by GC analysis) as a colorless oil.

EXAMPLE 5

Preparation of methyl 1-(2,3,5-tri-O-acetyl-beta-L-ribofuranosyl)-1,2,4-triazole-3-carboxylate from alpha-1,2,3,5-tetra-O-acetyl-L-ribofuranose

A 250 ml flask was charged with 1.92 g of triazole methylester and a solution of 4.8 g of the pure alpha-1,2,3,5-tetra-O-acetyl-L-ribofuranose, prepared in Example 4 in 50 ml of methyl acetate. The mixture was concentrated at atmospheric pressure to almost dryness (bath temperature: 90°C). To this mixture was added a solution of 22.7 mg of trifluoromethane sulfonic acid (triflic acid) in 1 ml of methyl acetate. The mixture was stirred at 115±5°C (pot temperature) under vacuum (30 mbar) for 4h. Upon the completion of the reaction the mixture was cooled to 70°C and to it was added 23 ml of ethyl alcohol. When a homogeneous solution was formed the mixture was cooled to 50°C and held until heavy precipitation formed. The mixture was then slowly cooled to -5°C (bath temperature) in 2h and held for 13 h. The solid was filtered, washed with 20 ml of cold ethyl alcohol, and dried under vacuum at 50°C for 17h to give 4.1 g (70% yield) of methyl 1-(2,3,5-tri-O-acetyl-beta-L-ribofuranosyl)-1,2,4-triazole-3-carboxylate as an off-white solid.


- 13 -

Upon reading the present specification various alternative embodiments will become obvious to the skilled artisan. These variations are to be considered within the scope and spirit of the subject invention, which is only to be limited by the claims that follow and their equivalents.

- 14 -

Claims


1. Process for producing methyl 1-(2,3,5-tri-O-acetyl- β -L-ribofuranosyl)-1,2,4-triazole-3-carboxylate of the formula:



5


IV

from a 1,2,3,5-tetra-O-acetyl-L-ribofuranose of the formula:




II

- 10 comprising reacting 1,2,3,5-tetra-O-acetyl-L-ribofuranose which contains at least 10 mole % of the alpha anomer of the formula:



II-B

- 15 with a triazole methylester of the formula:




III

2. Process of claim 1, wherein the 1, 2, 3, 5-tetra-O-acetyl-L-ribofuranose is a mixture of the α - and β -anomers wherein the mole ratio of the β -anomer to the α -anomer is from about 2:1 to about 3:1.

5 3. Process of claim 1, when the 1, 2, 3, 5 tetra-O-acetyl-L-ribofuranose is the pure α -anomer.


4. Process of claims 1 to 3, wherein the 1, 2, 3, 5- tetra-O-acetyl-L-ribofuranose of formula II is formed from L-ribose of the formula



V

10

which is reacted with a lower alkanol in the presence of a strong inorganic acid to an acetal of the formula:



VI

15

wherein R is lower alkyl


said acetal is acetylated in a solution of acetic acid, by treating said acetic acid solution with acetic anhydride acid and thereafter by adding a strong inorganic acid to said acetic solution to form 1, 2, 3, 5 tetra-O-acetyl-L-ribofuranose of formula II.

20

5. Process of claim 4, wherein the lower alkanol is methanol and accordingly R is methyl.

- 16 -


6. Process of claim 4 or 5, wherein the strong inorganic acid is sulfuric acid.
7. Process of claims 4 to 6, wherein both the conversions to the acetal of formula VI and the conversion to the 1, 2, 3, 5 tetra-O-acetyl-L-ribofuranose of formula II is performed at a temperature of about 0°C to 30°C.
8. Process of claims 4 to 7, wherein the acid treated acetic acid solution is neutralized with a base.
9. Process for producing levovirin of the formula



I

wherein the process comprises a process of claims 1 to 8.

10. The pure α -1, 2, 3, 5- tetra-O-acetyl-L-ribofuranose of the formula



II-B

which is substantially free of the corresponding β -anomer.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/08627

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07H19/056

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 03 011883 A (BANFI ALDO ;DALL ORO BRUNO (IT); FRIGERIO MARCO (IT); MANCINI ALFR) 13 February 2003 (2003-02-13) the whole document	1-10
A	US 6 130 326 A (AVERETT DEVRON ET AL) 10 October 2000 (2000-10-10) figure 1 examples 1-3B	
A	RAMASAMY, KANDA S. ET AL: "Monocyclic L-Nucleosides with Type 1 Cytokine-Inducing Activity" JOURNAL OF MEDICINAL CHEMISTRY (2000), 43(5), 1019-1028 , 2000, XP002258899 cited in the application scheme 1	

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

24 October 2003

Date of mailing of the international search report

10/11/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Klein, D

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/08627

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03011883	A	13-02-2003	EP 1281715 A1	05-02-2003
			WO 03011883 A2	13-02-2003
			WO 03011884 A1	13-02-2003
US 6130326	A	10-10-2000	US 2003018186 A1	23-01-2003
			US 6552183 B1	22-04-2003
			AT 236921 T	15-04-2003
			AT 238328 T	15-05-2003
			AU 738170 B2	13-09-2001
			AU 4986797 A	11-05-1998
			BR 9712527 A	08-03-2000
			CN 1268140 A	27-09-2000
			CZ 9901206 A3	15-09-1999
			DE 69720811 D1	15-05-2003
			DE 69721339 D1	28-05-2003
			DK 1132393 T3	21-07-2003
			DK 1027359 T3	11-08-2003
			EP 1132393 A1	12-09-2001
			EP 1254911 A1	06-11-2002
			EP 1302474 A1	16-04-2003
			EP 1027359 A2	16-08-2000
			HU 0001107 A2	28-06-2001
			JP 2002503212 T	29-01-2002
			JP 2003176296 A	24-06-2003
			KR 2000049224 A	25-07-2000
			NO 991785 A	15-06-1999
			NZ 334915 A	24-11-2000
			PL 333419 A1	06-12-1999
			RU 2188828 C2	10-09-2002
			SI 20076 A	30-04-2000
			SK 47199 A3	11-12-2000
			WO 9816186 A2	23-04-1998
			US 2002095033 A1	18-07-2002